Q-omics provides the consensus-scored FRMD3 profile across patient tissues and cancer cell-line models. FRMD3 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, FRMD3 is differentially expressed in 14, with the highest sampling consensus in KICH. Additionally, FRMD3 RNA expression shows 19,215 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, KICH, and THYM as cancer lineages where FRMD3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FRMD3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FRMD3 survival associations across molecular data types. FRMD3 RNA expression shows survival associations in the most cancer types (18), followed by mutation status (7) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FRMD3 RNA expression–survival associations across cancer types. High FRMD3 expression shows unfavorable associations in UVM and LGG, but favorable associations in KIRC, SKCM, THCA and LIHC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for FRMD3 RNA expression.
This table summarizes FRMD3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 4. The strongest signals are observed in BLCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for FRMD3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FRMD3 shows lower tumor expression in KICH, COAD, BLCA, LUSC and LUAD and higher tumor expression in THCA. The KICH box plot shows higher FRMD3 RNA expression in normal versus tumor tissue (log2 FC = −3.156, t-test p < 0.001).
This table shows molecular features associated with FRMD3 in patient tissues and cancer cell lines. In patient samples, FRMD3 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, FRMD3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Myeloma, while CRISPR and shRNA rows add functional-dependency signals in CNS and SOFT_TISSUE.
